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Streptococcus pneumonia infection is a major cause of
morbidity and mortality worldwide.1 Following the intro-
duction of pneumococcal conjugate vaccines (PCVs), the
incidence of invasive pneumococcal diseases (IPDs) has
decreased.1 Seven-valent PCV (PCV7) has been available in
Taiwan since late 2005. Serotype 19A, which is a non-PCV7
serotype, became the most prevalent S. pneumoniae
serotype in 2010.1 A national booster program, providing a
single dose of 13-valent PCV (PCV13) to children aged be-
tween 2 years and 5 years, was implemented in Taiwan in
2013.2 IPD due to serotype 19A increased significantly, from
1.7 cases/100,000 people in 2008 to 10.3 cases/100,000
people in 2012, followed by a substantial decrease to 5.6
cases/100,000 people in 2013.2
However, a 4-year-old female, vaccinated with three
doses of PCV7 and one PCV13 booster, suffered from sero-
type 19A-induced IPD; her infection was sufficiently severe
such that cardiopulmonary-cerebral resuscitation (CPCR)
and endotracheal intubation were performed in response to
pulseless electrical activity (PEA). Nonsurgical treatment* Corresponding author. 5 Fu-Hsin Street, Kweishan, Taoyuan 333,
Taiwan.
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tion efficacy.
2. Case report
A female aged 4 years and 8 months, without any under-
lying disease, received PCV7 vaccinations at 2 months, 4
months, and 6 months of age, and PCV13 at 17 months.
Fever and cough were present for 2 days. Due to the pro-
gressive weakness and body pain, the patient was taken to
our pediatric emergency department. Chest X-ray revealed
severe pneumonia and whiteout of the right, middle, and
lower lung (Figure 1A). The patient’s white blood cell count
was 5600 mL, with 24% band, C-reactive protein of 423 mg/
L, procalcitonin of 39.33 ng/mL, and creatinine of 1.36 mg/
dL.
Following admission to the pediatric intensive care unit
(in early September, 2014), we administered vancomycin
and cefotaxime. CPCR and endotracheal intubation were
performed due to PEA. Streptococcus pneumonia 19A,
showing susceptibility to penicillin (minimal inhibitory
concentrationZ 1.5 mg/L), ceftriaxone (minimal inhibitory
concentrationZ 1.0 mg/L) and vancomycin, was identified
using the capsular swelling method from both blood and
pleural cultures following chest tapping on the day of
admission. Invasive pneumococcus bacteremia, accompa-
nied by necrotizing pneumonia of the right lower lobe,
septic shock, and pericardial effusion, was diagnosed onby Elsevier Taiwan LLC. This is an open access article under the
/4.0/).
Figure 1 (A) Chest X-ray on admission (Day 1) revealed increased infiltration, partial consolidation, and pleural effusion on
bilateral lungs; (B) chest computed tomography on Day 5 postadmission revealed necrotizing pneumonia in the right lung, left
upper and lower lobes, right pneumothorax, bilateral pleural effusion; and (C) pericardial effusion (indicated by arrows).
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Friedenreich antigen (T-antigen; 3þ) and Coombs test re-
sults were positive; hemolytic uremic syndrome was also
indicated. Pneumothorax and subcutaneous emphysema
were detected on Day 4, and a pigtail catheter was inser-
ted. Pericardial effusion was aggravated on echocardiog-
raphy on Day 10; therefore, a further pigtail was inserted
and yellow turbid effusion which showed positive S. pneu-
moniae antigen was drained out. We also assessed immune
function on Day 5; no human immunodeficiency virus anti-
gen/antibody reaction and a T-cell count <200 normalized
by Week 6.
After the patient’s respiratory pattern became normal
without respiratory distress, she was discharged on post-
admission Day 47, provided with oral Augmentin for
continued use, and advised to attend the outpatient
department for follow up. Chest X-ray was performed on
Day 61; only mild bilateral effusion and right lower lobe
patch opacity were detected, with no dyspnea and normal
respiration.
3. Discussion
PCV-13 has also proven effective for both IPD and
community-acquired pneumonia in pediatric patients inTaiwan and Latin American countries.3 In a Swedish study,
PCV7 and PCV13 vaccination were associated with a 66%
lower risk of hospitalization for sinusitis and a 19% lower
risk of hospitalization for pneumonia in children aged 0e2
years in a comparison of data from 4 years prior to and 4
years after vaccine introduction.4 Providing timely and
effective antibiotics for invasive infection is of key impor-
tance for treatment success, particularly with respect to
aggressive, broad-spectrum antibiotics.5
Severe pneumonia with empyema and bacteremia
infected by S. pneumoniae serotype 19A have been re-
ported in children immunized with 10-valent pneumococcal
conjugate vaccine (PCV10).6,7 In our case, the patient
received three doses of PCV7 and a single dose of PCV13;
the PCV13 vaccination failed to prevent serotype 19A. A
single dose of PCV13 may not be adequate for the six
additional vaccine types provided by PCV13. We recom-
mend a treatment program comprising more doses of
PCV13. A national 2 þ 1 PCV13 (two doses for patients
aged < 6 months plus a booster after 1-years-of-age)
vaccination program implemented in Taiwan since 2015 will
benefit children with stronger prevention; however, close
surveillance of its preventive effect and possible changes in
serotypes of S. pneumonia is still necessary in the future.
We agree with Lu et al6 and Ho et al7 that physicians should
78 C.-T. Wu et alkeep in mind that invasive S. pneumoniae serotype 19A
infections were able to occur even in children immunized
with PCV10 or PCV13.6,7
To the best of our knowledge, this is the first report
describing successful CPCR and antibiotic treatment in
pneumococcus serotype 19A-induced severe IPD, with
impending mortality due to PEA in a 4-year-old female who
had received three doses of PCV7 and one PCV13 booster
vaccination. Aggressive antibiotic treatment and resusci-
tation procedures saved the patient’s life. PCV13 de-
creases non-PCV7 serotype IPD incidence, particularly
those associated with serotype 19A. In order to prevent
severe IPD worldwide, we recommend a multiple-dose
PCV13 vaccination program such as the new national 2 þ 1
PCV13 vaccination program implemented in Taiwan since
2015, instead of the previously applied single PCV13
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